Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare blood cancers: first human trial of PRT12396 begins

NCT ID NCT07469891

First seen Mar 20, 2026 · Last updated Jun 18, 2026 · Updated 13 times

Summary

This early-stage study tests a new drug, PRT12396, in about 100 people with polycythemia vera or myelofibrosis—rare blood cancers. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug controls the disease, but this is not a cure and long-term management is expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BRCR Global - Coral Springs

    RECRUITING

    Coral Springs, Florida, 33065, United States

  • Colorado Blood Cancer Institute

    RECRUITING

    Denver, Colorado, 80218, United States

  • START Midwest, LLC

    RECRUITING

    Grand Rapids, Michigan, 49546, United States

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

  • Tristar BMT

    RECRUITING

    Nashville, Tennessee, 37203, United States

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.